Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
On Friday, Beijing announced that a trade-in program that previously applied to big appliances and cars will now be widened to smartphones.
As the New Year rolls in, Wall Street is preparing for a slew of listing announcements from private equity-backed firms.
It’s understandable if you failed to notice one meaty if unglamorous trend on Wall Street: Private equity’s love affair with franchising.